<DOC>
	<DOC>NCT02920801</DOC>
	<brief_summary>In this study, the investigators aim to investigate whether saxagliptin modulate endothelial progenitor cells number and flow-mediated dilation in newly diagnosed, treatment-naive type 2 diabetic patients.</brief_summary>
	<brief_title>Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>newly diagnosed type 2 diabetics (diagnosis were made according to the American Diabetes Association Guideline [19] ), treatment naive, age 3075, hemoglobin A1c (HbA1c) â‰¥6.5%, fasting cpeptide &gt;1.0ng/L pregnancy or lactation, smoker, acute disease or infection, chronic renal disease (estimated glomerular filtration rate &lt;60 mL/min/1.73m2), live enzymes 3 times above the normal range, positive islet autoantibody, fasting cpeptide &lt;1.0ng/L, severe hypertriglyceridemia (triglyceride &gt;5.6mmol/L), cardiovascular events or surgery within 3 months, taking glucocorticoid, history of acute or chronic pancreatitis, pancreatic tumor, severe cardiac or pneumonic disease.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>saxagliptin</keyword>
	<keyword>endothelial progenitor cell</keyword>
	<keyword>flow-mediated dilation</keyword>
</DOC>